Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile

INTRODUCTION: Inhaled corticosteroid/long-acting β(2)-adrenoceptor agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently recommended as controller option at asthma Step 4 and as preferred treatment at asthma Step 5, but no research investigated the poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogliani, Paola, Cavalli, Francesco, Chetta, Alfredo, Cazzola, Mario, Calzetta, Luigino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091690/
https://www.ncbi.nlm.nih.gov/pubmed/35573127
http://dx.doi.org/10.2147/JAA.S283489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091690/
https://www.ncbi.nlm.nih.gov/pubmed/35573127
http://dx.doi.org/10.2147/JAA.S283489

Ejemplares similares